When a regulatory affairs manager at a mid-sized biotech needs to know whether the FDA has ever approved a similar drug formulation, the hunt begins. Guidances. Clinical trial databases. Precedent reviews stretching back years. Three weeks later, if the team is lucky, they have an answer. Maybe.
Rhizome AI thinks it can do better. Minutes better.
The Jersey City startup, fresh from Y Combinator's Winter 2026 cohort, is selling something pharma companies have wanted for decades: a way to get regulatory answers without the archeological dig. Its platform, Rhizome Ask, chews through up to 1,000 documents per query—FDA guidances, EMA opinions, ICH principles, clinical trial filings—and spits back answers with page-level citations. Not summaries. Not approximations. Direct links to the paragraph in question.
"We pair LLMs with a validation layer that displays exact paragraphs and sources," founder Chetan Mishra told the Center for Data Innovation in February. The system ingests more than 2.5 terabytes of public regulatory data from the FDA, EMA, and agencies in the U.K. and four other regions. According to the company, it hasn't hallucinated once in 2025—a bold claim in an industry where a single compliance error can torpedo a drug approval.
Whether that claim holds under real-world pressure is the question pharma buyers will ask before they sign.
From Zero to Six Figures in a Market That Moves Slowly
Rhizome AI hit six-figure revenue in 2025, its first full year, according to the startup's Y Combinator profile. Not bad for a company selling into an industry notorious for slow procurement cycles and risk aversion.
The company positions itself within what it describes as an "$8 trillion market cap" of pharmaceutical and biotech firms—a reference to the combined valuation of global biopharma leaders. GlobalData estimated the top 20 firms alone were worth roughly $3.8 trillion as of Q3 2025, so the addressable market math checks out, if you squint. What matters more is whether regulatory teams actually trust the product enough to replace the human legwork.
Customer testimonials on Rhizome's site mention "weeks-to-minutes" acceleration, though the company hasn't yet published named case studies or third-party accuracy audits. The product is live with "large pharma and independent consultants," per the homepage, used by everyone from VPs of regulatory affairs to device engineers. A decent start, though enterprise software veterans know testimonials are table stakes. Logo slides and retention data tell the real story.
An Infrastructure Engineer Takes on Pharma Bureaucracy
Mishra didn't come up through regulatory affairs. He built AI infrastructure. Before Rhizome, he was the first product engineer at EvolutionaryScale, where he created an inference platform for protein design that handled billions of API calls and reached tens of thousands of users. Earlier, he was employee number 16 at Instabase, closing $7 million in technical deals for banks and insurers.
That technical background shows. Rhizome's "Source Viewer" jumps straight to specific pages in authoritative documents, treating AI not as an oracle but as a research assistant you can fact-check. It's a design choice that might actually resonate with compliance-obsessed buyers who've been burned by overconfident automation before.
Mishra's stated goal, laid out in the Center for Data Innovation interview, is to compress regulatory analysis, precedent review, and documentation cycles down to five days. Clinical trials still take years—you can't AI your way past biology. But the paperwork? That's software's domain.
Pricing Like a SaaS Startup, Selling to Pharma Giants
The pricing structure feels almost... consumer-friendly. At least by pharma software standards.
Rhizome offers self-serve access starting at $400 per month for its Project plan, which covers FDA premarket and postmarket databases, EMA datasets, and guidance from four other regions. A Professional single-seat annual plan runs $3,500. The Business tier costs $20,000 per year for five seats and includes monthly office hours and invoice billing.
It's a bottoms-up strategy: hook consultants and small regulatory teams, prove value, then climb into enterprise accounts. The company also maintains a library of articles on FDA and EMA precedents across drugs, biologics, and combination products—classic content marketing designed to capture practitioners Googling for regulatory guidance at 11 p.m. on a Sunday.
Whether credit-card self-serve can scale into the seven-figure enterprise deals that define pharma software remains an open question. Selling to compliance teams is different from selling to developers. The buying cycle is longer, the validation deeper, the security reviews more exhausting. Rhizome will need to prove it can navigate that gauntlet.
A Market Full of Players, None Dominant
The regulatory AI space is getting crowded, fast. But nobody's won yet.
Clarivate launched an AI-powered regulatory assistant within its Cortellis suite last August, claiming coverage across more than 80 markets. Rimsys, which focuses on MedTech regulatory information management, announced Rimsys AI in September and partnered with Clarivate for intelligence integration. Weave Bio debuted HAQ Manager in November to speed up health authority question responses. Redica Systems specializes in FDA enforcement documents—483s, warning letters, the paper trail of compliance failures. E-Biotech announced AI regulatory infrastructure in February.
The sheer breadth of entrants suggests the market hasn't settled on a winner. Maybe there's room for a focused intelligence layer that sits above workflow tools and below document management systems. Or maybe the space fragments further, with point solutions for every slice of the regulatory workflow.
Rhizome's bet is simple: regulatory teams want fast, traceable answers more than they want another system of record. They're drowning in documents, not starved for storage.
The Hard Part Comes Next
Six figures in revenue is a milestone. It's not a business model. Not yet.
The real test for Rhizome arrives when enterprise buyers start kicking the tires. When legal teams demand security audits. When quality assurance leaders ask for validation studies. When a single hallucination in a regulatory submission could cost a company millions in delays or, worse, a failed approval.
Mishra's claim—zero hallucinations in 2025—is either the foundation of a defensible moat or a ticking time bomb. Pharma doesn't forgive mistakes. If the product delivers on that promise at scale, Rhizome could become essential infrastructure for an industry desperate to move faster. If it doesn't, the company will join the long list of AI startups that oversold accuracy and undersold risk.
For now, Rhizome is doing what every early-stage software company does: land customers, prove value, iterate fast. The difference is the stakes. In consumer software, a bug means angry users. In regulatory software, a bug could mean a recalled drug or a shelved therapy.
That's the market Chetan Mishra chose to tackle. No pressure.
